Overview:

**COVID-19 RELATION**
Losartan potassium is an active, nonpeptide angiotensin II (AII) receptor antagonist, and has high affinity and selectivity against to the AII subtype 1 (AT(1)) receptor. it is currently being used as a treatment option against hypertension. SARS-CoV-2 infects the human cells by its Spike (S) protein binding to the human ACE2 cell receptor. Renin-Angiotensin-Aldosterone System Inhibitors such losartan are being investigated for their unconventional role in inhibiting SARS-CoV-2/ACE2 fusions at the moment as a possible treatment option to solve the COVID-19 crisis**

Non-peptide angiotensin II receptor antagonist (1,2). Clinically useful antihypertensive agent (3). Inhibits collagen I synthesis (4). Induces SIRT1 expression and activity and reduces hepatic injury in a rat reduced-size orthotopic liver transplantation model (5). Displays neuroprotective effects alone with nimesulide against chronic fatigue stress (6). Displays myocardial antifibrotic activity (7).

References:

1. Merck 14: 5583

2. AT Chiu et al. J. Pharmacol. Exp. Ther. 1990 252:711

3. M McIntyre et al. Pharmacol. Ther. 1997 74:181

4. B. Diop-Frimpong et al. Proc. Natl. Acad. Sci. USA 2011 108:2909

5. E Pantazi et al. World J. Gastroenterol. 2015 21:8021

6. A Kumar et al. Inflammopharmacology 2015 23:291

7. JL Miguel-Carrasco et al. Sci. Rep. 2017 7:41865